CRIS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.25M

-2.86%

-0.432

-61.04%

3.00M

+26.05%

-0.300

-76%

3.15M

+14.59%

-0.310

-54.41%

Estimates Revision

The market is revising Upward the revenue expectations for Curis, Inc. (CRIS) for FY2025, with the revenue forecasts being adjusted by 4.41% over the past three months. During the same period, the stock price has changed by -46.30%.

Revenue Estimates for FY2025

Revise Upward

+4.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.28%

In Past 3 Month

Stock Price

Go Down

-46.30%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11.00 USD with a low forecast of 5.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

11.00

High

17.00

Current: 0.000

Low

5.00

Averages

11.00

High

17.00

Evercore ISI

Outperform

downgrade

$40 -> $38

2026-01-05

New

Reason

Evercore ISI

Price Target

$40 -> $38

2026-01-05

New

downgrade

Outperform

Reason

Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Canaccord

Kyle Mikson

Hold

maintain

$28 -> $30

2025-12-22

Reason

Canaccord

Kyle Mikson

Price Target

$28 -> $30

2025-12-22

maintain

Hold

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.

BofA

Buy

downgrade

$39 -> $35

2025-12-15

Reason

BofA

Price Target

$39 -> $35

2025-12-15

downgrade

Buy

Reason

BofA lowered the firm's price target on Caris Life Sciences to $35 from $39 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Canaccord

Hold

initiated

$28

2025-12-02

Reason

Canaccord

Price Target

$28

2025-12-02

initiated

Hold

Reason

Canaccord initiated coverage of Caris Life Sciences with a Hold rating and $28 price target. The company is well positioned in the precision oncology landscape with a "differentiated" multi-modal platform and early traction in both tissue- and blood-based therapy selection, the analyst tells investors in a research note. However, the firm thinks the stock's current valuation captures much of Caris Life's growth trajectory in therapy selection.

H.C. Wainwright

Buy

initiated

$17

2025-05-19

Reason

H.C. Wainwright

Price Target

$17

2025-05-19

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Curis with a Buy rating and $17 price target. Curis is a clinical-stage biopharmaceutical company developing novel therapies for cancer treatment, the analyst tells investors in a research note. The firm says the company's lead drug candidate, emavusertib, is a potential first-in-class oral, small molecule inhibitor of IRAK4, which mediates signaling downstream of toll-like receptor superfamily. It sees a "promising" early efficacy profile in the lead non-Hodgkin's lymphoma subtype being evaluated in TakeAim lymphoma.

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$20 → $16

2025-03-31

Reason

HC Wainwright & Co.

Edward White

Price Target

$20 → $16

2025-03-31

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Curis Inc (CRIS.O) is -0.74, compared to its 5-year average forward P/E of -4.74. For a more detailed relative valuation and DCF analysis to assess Curis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.74

Current PE

-0.74

Overvalued PE

2.28

Undervalued PE

-11.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.95

Current EV/EBITDA

-0.90

Overvalued EV/EBITDA

2.35

Undervalued EV/EBITDA

-8.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.91

Current PS

0.99

Overvalued PS

49.25

Undervalued PS

-9.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRIS News & Events

Events Timeline

No data

News

9.5

01-07Benzinga

Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4

9.5

01-07Benzinga

UniFirst Corp Reports Mixed Q1 Results, Shares Drop 4%

8.5

01-07Newsfilter

Curis Secures $80.8 Million PIPE Financing to Support R&D Efforts

People Also Watch

Frequently Asked Questions

What is Curis Inc (CRIS) stock price today?

The current price of CRIS is 0.87 USD — it has increased 3.57 % in the last trading day.

What is Curis Inc (CRIS)'s business?

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

What is the price predicton of CRIS Stock?

What is Curis Inc (CRIS)'s revenue for the last quarter?

Curis Inc revenue for the last quarter amounts to 3.18M USD, increased 8.36 % YoY.

What is Curis Inc (CRIS)'s earnings per share (EPS) for the last quarter?

Curis Inc. EPS for the last quarter amounts to -0.49 USD, decreased -71.18 % YoY.

What changes have occurred in the market's expectations for Curis Inc (CRIS)'s fundamentals?

How many employees does Curis Inc (CRIS). have?

Curis Inc (CRIS) has 33 emplpoyees as of January 08 2026.

What is Curis Inc (CRIS) market cap?

Today CRIS has the market capitalization of 10.86M USD.